<DOC>
	<DOCNO>NCT01316939</DOCNO>
	<brief_summary>A randomised , double-blind , placebo-controlled study evaluate efficacy safety two dos ( 500 mg daily 500 mg twice daily ) GSK1605786A maintain remission 52 week adult subject Crohn 's disease . Efficacy assess Crohn 's Disease Activity Index ( CDAI ) score . Eligible subject achieve response ( CDAI decrease least 100 point ) and/or remission ( CDAI less 150 ) prior GSK sponsor induction study . The primary endpoint proportion subject remission Weeks 28 52 . Safety assess record adverse event , clinical laboratory parameter include liver function test , vital sign electrocardiogram . Population pharmacokinetics evaluate two dos GSK1605786A . Health outcomes assessment include change Inflammatory Bowel Disease Questionnaire ( IBDQ ) , SF-36v2 , EQ-5D , Work Productivity Activity Impairment - Crohn 's Disease ( WPAI-CD ) disability .</brief_summary>
	<brief_title>GSK1605786A Maintenance Remission Subjects With Crohn 's Disease</brief_title>
	<detailed_description>This multi-centre , randomised , placebo-controlled , double-blind parallel group study adult subject Crohn 's disease previously achieve clinical response ( CDAI decrease least 100 point ) and/or remission ( CDAI less 150 ) prior Phase III induction study ( Study CCX114151 another GSK sponsor induction study ) . Subjects randomise 52 week oral treatment GSK1605786A 500 mg daily 500 mg twice daily placebo . Subjects receive concomitant corticosteroid entry undergo dose taper follow defined schedule . Subjects complete treatment period may eligible enter open-label extension study . Subjects experience disease worsen require additional ( rescue ) treatment withdrawn may eligible enter open-label study . Subjects enter open-label study must complete follow-up assessment 4 week completion treatment . Approximately 756 subject enrol .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects achieve clinical response ( CDAI decrease least 100 point ) and/or remission ( CDAI less 150 ) upon completion treatment Study CCX114151 another GSK sponsor induction study Written inform consent prior CCX114157 specific study procedure Females childbearing potential must sexually inactive commit use consistent correct use contraceptive method failure rate le 1 percent Stable dose Crohn 's disease medication Subjects corticosteroids entry must willing undergo corticosteroid dose taper study If female , pregnant , positive pregnancy test breastfeeding Subjects know suspected coeliac disease positive screening test ( antitissue transglutaminase antibody ) exclude enrolment induction study . Subjects diagnosis coeliac disease subsequently suspect exclude test antitissue transglutaminase antibodies prior enrolment maintenance study . Known suspect fixed symptomatic small bowel stricture Enterocutaneous , abdominal pelvic fistulae likely require surgery study period Current sepsis infection require intravenous antibiotic therapy great 2 week Evidence hepatic dysfunction , viral hepatitis , liver function abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Crohn 's disease , oral CCR9 antagonist , placebo-controlled , maintenance remission , 52-week treatment , quality life</keyword>
</DOC>